PF 6647263

Drug Profile

PF 6647263

Alternative Names: Anti-EFNA4-ADC; Anti-EFNA4-monoclonal-antibody-calicheamicin-conjugate; PF 06647263; PF-0667263; PF-6647263

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Eph family receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Soild tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 May 2017 Pfizer completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02078752)
  • 13 Apr 2016 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top